

## Cadonilimab: Adis Evaluation

### Key Points

- A PD-1/CTLA-4 bi-specific antibody being developed by Akeso, Inc. for the treatment of a wide range of solid tumours
- Received its first approval on 29 June 2022 in China
- Approved for use in patients with r/mCC who have progressed on or after platinum-based chemotherapy

### Summary

Cadonilimab (开坦尼®), a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumours, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, oesophageal squamous cell cancer, liver cancer and nasopharyngeal cancer.

Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.